Related Experiment Video
Updated: Jan 30, 2026
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
OLFML2A mediates cell cycle regulation in triple-negative breast cancer via EZH2
Haining Ding1, Yian Chen1, Qinghong Yu1
1The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
Background:
Triple-negative breast cancer (TNBC) is recognized as one of the most aggressive and prognostically adverse subtypes of breast cancer. The lack of effective therapeutic targets presents substantial challenges, including impediments in early diagnosis, restricted treatment options, and a pronounced tendency for drug resistance. Despite recent advancements in the diagnosis and management of TNBC, the overall survival rate for patients remains suboptimal. Consequently, gaining a more profound understanding of its biological mechanisms and developing novel therapeutic strategies are imperative scientific priorities in this domain.
Methods:
OLFML2A was identified as a potential therapeutic target in TNBC through analyses of the Human Protein Atlas and Kaplan-Meier databases. Its functional role was investigated using OLFML2A knockout (KO) and overexpression (OE) models in MDA-MB-231 cells. Effects on proliferation, cell cycle, and apoptosis were assessed by EdU assays, flow cytometry, RT-qPCR, western blotting, and immunofluorescence. Tumor growth and body weight were monitored in vivo, and tumor tissues were examined by H&E staining, RT-qPCR, and western blotting. Proteomic profiling integrated with literature mining identified EZH2 as a key downstream candidate. Their interaction was validated by co-immunoprecipitation, and EZH2 expression and localization under different OLFML2A conditions were analyzed. Rescue experiments using the EZH2 inhibitor GSK126 assessed the functional output of the OLFML2A-EZH2 axis via CCK-8, EdU assays.
Results:
OLFML2A acts as an oncogenic gene in triple-negative breast cancer. The silencing of OLFML2A markedly reduced the proliferation of MDA-MB-231 cells, induced cell cycle arrest at the G1 phase, and inhibited tumor growth. In contrast, overexpression of OLFML2A reversed these effects. Comprehensive proteomic and molecular biology analyses further indicated that OLFML2A may play a role in cell cycle regulation through the modulation of EZH2.
Conclusions:
Our findings suggest that OLFML2A may facilitate cell cycle progression by regulating EZH2, implicating it as a potential therapeutic target for triple-negative breast cancer.
Insights
OLFML2A promotes triple-negative breast cancer (TNBC) growth by regulating cell cycle progression via EZH2. Silencing OLFML2A inhibits TNBC proliferation and tumor growth, suggesting OLFML2A as a potential therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Triple-negative breast cancer (TNBC) is an aggressive subtype with poor prognosis and limited therapeutic options.
- Identifying novel therapeutic targets is crucial for improving TNBC patient outcomes.
- Understanding the molecular mechanisms driving TNBC progression is a key research priority.
Purpose of the Study:
- To investigate the role of OLFML2A as a potential therapeutic target in triple-negative breast cancer.
- To elucidate the functional mechanisms by which OLFML2A influences TNBC cell behavior.
- To explore the relationship between OLFML2A and EZH2 in TNBC pathogenesis.
Main Methods:
- Functional analysis of OLFML2A using knockout and overexpression models in MDA-MB-231 TNBC cells.
- Assessment of cell proliferation, cell cycle, and apoptosis using various assays (EdU, flow cytometry, RT-qPCR, western blotting, immunofluorescence).
- In vivo tumor growth monitoring and proteomic profiling to identify downstream targets, including EZH2, with validation through co-immunoprecipitation and rescue experiments.
Main Results:
- OLFML2A acts as an oncogene in TNBC, with its silencing reducing cell proliferation and inducing G1 phase cell cycle arrest.
- Overexpression of OLFML2A reversed these inhibitory effects, promoting TNBC cell growth.
- Proteomic and molecular analyses indicated OLFML2A regulates EZH2, suggesting a role in cell cycle control.
Conclusions:
- OLFML2A facilitates cell cycle progression in TNBC, potentially by modulating EZH2.
- OLFML2A represents a promising therapeutic target for triple-negative breast cancer.
- Further research into the OLFML2A-EZH2 axis could lead to novel treatment strategies for TNBC.
Related Concept Videos
01:23Negative Regulator Molecules
01:22Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
02:58Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
00:56What is the Cell Cycle?
01:04What is the Cell Cycle?
01:28pH Regulation in Cells
Cytosolic pH
Under physiological conditions, the cytosolic pH is slightly more acidic than the extracellular pH. However, cells must prevent further acidification of their cytosol to...